English

Arcus Biosciences, Inc.

EDGAR

RCUS Current report (8-K) · filed 2026-10-23

Annual consolidated revenue for 2025: about USD 33M, using the latest reported figures. The previous period, 2024, was about USD 51M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

33 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 33000000 USD Source

Operating margin

-290.91%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -96000000 USD Source
Revenue: 33000000 USD Source

Operating cash flow

-119 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -257000000 USD Source
Operating Cash Flow: -138000000 USD Source

Free cash flow

-119 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -257000000 USD Source
Operating Cash Flow: -138000000 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 150 million USD 2026-06-30 Source
Exact value

150000000 USD
Long-term debt including current maturities: 101 million USD 2026-06-30 Source
Exact value

101000000 USD
Shares outstanding: 127 million shares 2026-06-30 Source
Exact value

127000000 shares

Reported share-count change

19.36% · 20.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

106400000 shares · 2025-06-30· Source
127000000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

57 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 6000000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 33000000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 22000000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 7000000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 33000000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-460 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -135000000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -353000000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -247000000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -128000000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -91000000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-474 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -362000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -265000000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -482000000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -362000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -138000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -257000000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -138000000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 1000000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1000000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2000000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1000000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-475 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -362000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -265000000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -482000000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -362000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -138000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -257000000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -138000000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1000000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1000000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2000000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1000000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-23.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 9 of 11 periods available· newest 2025-12-31
Total liabilities: 5 of 11 periods available· newest 2021-12-31
Current assets: 9 of 11 periods available· newest 2025-12-31
Current liabilities: 9 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2025-12-31
Shares outstanding: 9 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-35.3%

Prior period

USD 51 million

2024-01-01 – 2024-12-31
Current period

USD 33 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

33000000 − 51000000 = -18000000 USD

51000000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
33000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Year-over-year change in Revenue: -18000000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 33000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1305258 Filing: 000172452126000009 Input fundies:Revenue: 51000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1306031 Filing: 000172452126000009
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 70 million

Prior period

−USD 283 million

2024-01-01 – 2024-12-31
Current period

−USD 353 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-353000000 − -283000000 = -70000000 USD

-283000000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-353000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Year-over-year change in Net income: -70000000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -353000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1495416 Filing: 000172452126000009 Input fundies:NetIncome: -283000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1496157 Filing: 000172452126000009
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 312 million

Prior period

−USD 170 million

2024-01-01 – 2024-12-31
Current period

−USD 482 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-482000000 − -170000000 = -312000000 USD

-170000000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-482000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Year-over-year change in Operating cash flow: -312000000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -482000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1146709 Filing: 000172452126000009 Input fundies:OperatingCashFlow: -170000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1147334 Filing: 000172452126000009
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-66.7%

Prior period

USD 6 million

2024-01-01 – 2024-12-31
Current period

USD 2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2000000 − 6000000 = -4000000 USD

6000000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Year-over-year change in Capital expenditure: -4000000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1155638 Filing: 000172452126000009 Input fundies:CapitalExpenditure: 6000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1156194 Filing: 000172452126000009
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 33 million 100% of revenue
Operating costs Derived USD 419 million 1,270% of revenue
Operating income −USD 386 million −1,170% of revenue
Tax, interest and other Derived −USD 33 million −100% of revenue
Net income −USD 353 million −1,070% of revenue

Cash

Operating cash flow −USD 482 million −1,461% of revenue
Capital expenditure USD 2 million 6.1% of revenue
Free cash flow Derived −USD 484 million −1,467% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 3,882% of revenue.
2018 Operating loss: operating costs were 757% of revenue.
2019 Operating loss: operating costs were 691% of revenue.
2020 Operating loss: operating costs were 259% of revenue.
2021 14%86%
2022 Operating loss: operating costs were 837% of revenue.
2023 Operating loss: operating costs were 1,019% of revenue.
2024 Operating loss: operating costs were 747% of revenue.
2025 Operating loss: operating costs were 1,270% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	1413000	54854000 Derived	-53441000	-359000 Derived	-53082000	-30573000 Derived	Source 2017-01-01 – 2017-12-31: 1413000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -53441000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -53082000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -25059000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 5514000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	8353000	63212000 Derived	-54859000	-5265000 Derived	-49594000	-46739000 Derived	Source 2018-01-01 – 2018-12-31: 8353000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -54859000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -49594000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -42996000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 3743000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	15000000	103709000 Derived	-88709000	-3999000 Derived	-84710000	-75387000 Derived	Source 2019-01-01 – 2019-12-31: 15000000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -88709000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -84710000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -73462000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1925000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	78000000	202000000 Derived	-124000000	-1000000 Derived	-123000000	108000000 Derived	Source 2020-01-01 – 2020-12-31: 78000000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -124000000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -123000000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 111000000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3000000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	383000000	329000000 Derived	54000000	1000000 Derived	53000000	-282000000 Derived	Source 2021-01-01 – 2021-12-31: 383000000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 54000000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 53000000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -256000000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 26000000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	38000000	318000000 Derived	-280000000	-13000000 Derived	-267000000	432000000 Derived	Source 2022-01-01 – 2022-12-31: 38000000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -280000000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -267000000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 438000000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 6000000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	37000000	377000000 Derived	-340000000	-33000000 Derived	-307000000	-330000000 Derived	Source 2023-01-01 – 2023-12-31: 37000000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -340000000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -307000000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -306000000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 24000000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	51000000	381000000 Derived	-330000000	-47000000 Derived	-283000000	-176000000 Derived	Source 2024-01-01 – 2024-12-31: 51000000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -330000000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -283000000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -170000000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 6000000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	33000000	419000000 Derived	-386000000	-33000000 Derived	-353000000	-484000000 Derived	Source 2025-01-01 – 2025-12-31: 33000000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -386000000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -353000000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -482000000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 2000000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 33M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	1413000	Revenue: 1413000 Open source
20182018-12-31	Revenue	8353000	Revenue: 8353000 Open source
20192019-12-31	Revenue	15000000	Revenue: 15000000 Open source
20202020-12-31	Revenue	78000000	Revenue: 78000000 Open source
20212021-12-31	Revenue	383000000	Revenue: 383000000 Open source
20222022-12-31	Revenue	38000000	Revenue: 38000000 Open source
20232023-12-31	Revenue	37000000	Revenue: 37000000 Open source
20242024-12-31	Revenue	51000000	Revenue: 51000000 Open source
20252025-12-31	Revenue	33000000	Revenue: 33000000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-35.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 1413000 Open source
20182018-12-31	Year over year	491.2%	Revenue: 8353000 Open source Revenue: 1413000 Open source
20192019-12-31	Year over year	79.6%	Revenue: 15000000 Open source Revenue: 8353000 Open source
20202020-12-31	Year over year	420%	Revenue: 78000000 Open source Revenue: 15000000 Open source
20212021-12-31	Year over year	391%	Revenue: 383000000 Open source Revenue: 78000000 Open source
20222022-12-31	Year over year	-90.1%	Revenue: 38000000 Open source Revenue: 383000000 Open source
20232023-12-31	Year over year	-2.6%	Revenue: 37000000 Open source Revenue: 38000000 Open source
20242024-12-31	Year over year	37.8%	Revenue: 51000000 Open source Revenue: 37000000 Open source
20252025-12-31	Year over year	-35.3%	Revenue: 33000000 Open source Revenue: 51000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,169.7% 2025

Net margin -1,069.7% 2025

Free cash flow margin -1,466.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-3,782.1%	Operating Income: -53441000 Open source Revenue: 1413000 Open source
20182018-12-31	Operating margin	-656.8%	Operating Income: -54859000 Open source Revenue: 8353000 Open source
20192019-12-31	Operating margin	-591.4%	Operating Income: -88709000 Open source Revenue: 15000000 Open source
20202020-12-31	Operating margin	-159%	Operating Income: -124000000 Open source Revenue: 78000000 Open source
20212021-12-31	Operating margin	14.1%	Operating Income: 54000000 Open source Revenue: 383000000 Open source
20222022-12-31	Operating margin	-736.8%	Operating Income: -280000000 Open source Revenue: 38000000 Open source
20232023-12-31	Operating margin	-918.9%	Operating Income: -340000000 Open source Revenue: 37000000 Open source
20242024-12-31	Operating margin	-647.1%	Operating Income: -330000000 Open source Revenue: 51000000 Open source
20252025-12-31	Operating margin	-1,169.7%	Operating Income: -386000000 Open source Revenue: 33000000 Open source
20172017-12-31	Net margin	-3,756.7%	Net Income: -53082000 Open source Revenue: 1413000 Open source
20182018-12-31	Net margin	-593.7%	Net Income: -49594000 Open source Revenue: 8353000 Open source
20192019-12-31	Net margin	-564.7%	Net Income: -84710000 Open source Revenue: 15000000 Open source
20202020-12-31	Net margin	-157.7%	Net Income: -123000000 Open source Revenue: 78000000 Open source
20212021-12-31	Net margin	13.8%	Net Income: 53000000 Open source Revenue: 383000000 Open source
20222022-12-31	Net margin	-702.6%	Net Income: -267000000 Open source Revenue: 38000000 Open source
20232023-12-31	Net margin	-829.7%	Net Income: -307000000 Open source Revenue: 37000000 Open source
20242024-12-31	Net margin	-554.9%	Net Income: -283000000 Open source Revenue: 51000000 Open source
20252025-12-31	Net margin	-1,069.7%	Net Income: -353000000 Open source Revenue: 33000000 Open source
20172017-12-31	Free cash flow margin	-2,163.7%	Revenue: 1413000 Open source Operating Cash Flow: -25059000 Open source Capital Expenditure: 5514000 Open source
20182018-12-31	Free cash flow margin	-559.5%	Revenue: 8353000 Open source Operating Cash Flow: -42996000 Open source Capital Expenditure: 3743000 Open source
20192019-12-31	Free cash flow margin	-502.6%	Revenue: 15000000 Open source Operating Cash Flow: -73462000 Open source Capital Expenditure: 1925000 Open source
20202020-12-31	Free cash flow margin	138.5%	Revenue: 78000000 Open source Operating Cash Flow: 111000000 Open source Capital Expenditure: 3000000 Open source
20212021-12-31	Free cash flow margin	-73.6%	Revenue: 383000000 Open source Operating Cash Flow: -256000000 Open source Capital Expenditure: 26000000 Open source
20222022-12-31	Free cash flow margin	1,136.8%	Revenue: 38000000 Open source Operating Cash Flow: 438000000 Open source Capital Expenditure: 6000000 Open source
20232023-12-31	Free cash flow margin	-891.9%	Revenue: 37000000 Open source Operating Cash Flow: -306000000 Open source Capital Expenditure: 24000000 Open source
20242024-12-31	Free cash flow margin	-345.1%	Revenue: 51000000 Open source Operating Cash Flow: -170000000 Open source Capital Expenditure: 6000000 Open source
20252025-12-31	Free cash flow margin	-1,466.7%	Revenue: 33000000 Open source Operating Cash Flow: -482000000 Open source Capital Expenditure: 2000000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -482M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-25059000	Operating Cash Flow: -25059000 Open source
20182018-12-31	Operating cash flow	-42996000	Operating Cash Flow: -42996000 Open source
20192019-12-31	Operating cash flow	-73462000	Operating Cash Flow: -73462000 Open source
20202020-12-31	Operating cash flow	111000000	Operating Cash Flow: 111000000 Open source
20212021-12-31	Operating cash flow	-256000000	Operating Cash Flow: -256000000 Open source
20222022-12-31	Operating cash flow	438000000	Operating Cash Flow: 438000000 Open source
20232023-12-31	Operating cash flow	-306000000	Operating Cash Flow: -306000000 Open source
20242024-12-31	Operating cash flow	-170000000	Operating Cash Flow: -170000000 Open source
20252025-12-31	Operating cash flow	-482000000	Operating Cash Flow: -482000000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -484M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	-30573000	Operating Cash Flow: -25059000 Open source Capital Expenditure: 5514000 Open source
20182018-12-31	Free cash flow	-46739000	Operating Cash Flow: -42996000 Open source Capital Expenditure: 3743000 Open source
20192019-12-31	Free cash flow	-75387000	Operating Cash Flow: -73462000 Open source Capital Expenditure: 1925000 Open source
20202020-12-31	Free cash flow	108000000	Operating Cash Flow: 111000000 Open source Capital Expenditure: 3000000 Open source
20212021-12-31	Free cash flow	-282000000	Operating Cash Flow: -256000000 Open source Capital Expenditure: 26000000 Open source
20222022-12-31	Free cash flow	432000000	Operating Cash Flow: 438000000 Open source Capital Expenditure: 6000000 Open source
20232023-12-31	Free cash flow	-330000000	Operating Cash Flow: -306000000 Open source Capital Expenditure: 24000000 Open source
20242024-12-31	Free cash flow	-176000000	Operating Cash Flow: -170000000 Open source Capital Expenditure: 6000000 Open source
20252025-12-31	Free cash flow	-484000000	Operating Cash Flow: -482000000 Open source Capital Expenditure: 2000000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

47.1% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Liabilities / assets	19.2%	Total Liabilities: 36618000 Open source Total Assets: 190486000 Open source
20182018-12-31	Liabilities / assets	14.5%	Total Liabilities: 39983000 Open source Total Assets: 274925000 Open source
20192019-12-31	Liabilities / assets	19.3%	Total Liabilities: 39268000 Open source Total Assets: 203110000 Open source
20202020-12-31	Liabilities / assets	35%	Total Liabilities: 269988000 Open source Total Assets: 772292000 Open source
20212021-12-31	Liabilities / assets	47.1%	Total Liabilities: 750448000 Open source Total Assets: 1592000000 Open source
2022-12-31	Liabilities / assets	Not reported	Total Assets: 1345000000 Open source
2023-12-31	Liabilities / assets	Not reported	Total Assets: 1095000000 Open source
2024-12-31	Liabilities / assets	Not reported	Total Assets: 1150000000 Open source
2025-12-31	Liabilities / assets	Not reported	Total Assets: 1139000000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.36× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Current assets / current liabilities	13.9×	Current Assets: 176869000 Open source Current Liabilities: 12726000 Open source
20182018-12-31	Current assets / current liabilities	15.29×	Current Assets: 258948000 Open source Current Liabilities: 16935000 Open source
20192019-12-31	Current assets / current liabilities	8.49×	Current Assets: 192705000 Open source Current Liabilities: 22706000 Open source
20202020-12-31	Current assets / current liabilities	6.05×	Current Assets: 735815000 Open source Current Liabilities: 121669000 Open source
20212021-12-31	Current assets / current liabilities	7.6×	Current Assets: 1262000000 Open source Current Liabilities: 166000000 Open source
20222022-12-31	Current assets / current liabilities	5.53×	Current Assets: 1067000000 Open source Current Liabilities: 193000000 Open source
20232023-12-31	Current assets / current liabilities	4.52×	Current Assets: 831000000 Open source Current Liabilities: 184000000 Open source
20242024-12-31	Current assets / current liabilities	4.5×	Current Assets: 1016000000 Open source Current Liabilities: 226000000 Open source
20252025-12-31	Current assets / current liabilities	4.36×	Current Assets: 1007000000 Open source Current Liabilities: 231000000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 17.97 million Exact value Exact value: -17970000 USD 2016-01-01 – 2016-12-31: -17970000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2016-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -17970000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17970000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#132933 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.	−USD 12.94 million Exact value Exact value: -12944000 USD 2016-01-01 – 2016-12-31: -12944000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2016-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -12944000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12944000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#164465 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.	USD 4.1 million Exact value Exact value: 4099000 USD 2016-01-01 – 2016-12-31: 4099000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2016-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 4099000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4099000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#166328 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.	−USD 17.04 million Calculation and evidence -12944000 − 4099000 USD Exact free cash flow: -17043000 USD 2016-01-01 – 2016-12-31: -12944000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 4099000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2016-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -17043000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12944000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#164465 Filing: 000156459019006274 Input fundies:CapitalExpenditure: 4099000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#166328 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 53.08 million Exact value Exact value: -53082000 USD 2017-01-01 – 2017-12-31: -53082000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2017-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -53082000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -53082000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#132779 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.	−USD 25.06 million Exact value Exact value: -25059000 USD 2017-01-01 – 2017-12-31: -25059000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2017-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -25059000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25059000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#164253 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.	USD 5.51 million Exact value Exact value: 5514000 USD 2017-01-01 – 2017-12-31: 5514000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2017-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 5514000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5514000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#166118 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.	−USD 30.57 million Calculation and evidence -25059000 − 5514000 USD Exact free cash flow: -30573000 USD 2017-01-01 – 2017-12-31: -25059000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 5514000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2017-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -30573000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25059000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#164253 Filing: 000156459019006274 Input fundies:CapitalExpenditure: 5514000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459019006274/rcus-20181231.xml#166118 Filing: 000156459019006274 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 49.59 million Exact value Exact value: -49594000 USD 2018-01-01 – 2018-12-31: -49594000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2018-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -49594000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49594000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459021008270/rcus-10k_20201231.htm#3515009 Filing: 000156459021008270 The citation records this snapshot. The page link may show a newer release later.	−USD 43 million Exact value Exact value: -42996000 USD 2018-01-01 – 2018-12-31: -42996000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2018-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -42996000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42996000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459021008270/rcus-10k_20201231.htm#2503603 Filing: 000156459021008270 The citation records this snapshot. The page link may show a newer release later.	USD 3.74 million Exact value Exact value: 3743000 USD 2018-01-01 – 2018-12-31: 3743000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2018-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 3743000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3743000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459021008270/rcus-10k_20201231.htm#2531465 Filing: 000156459021008270 The citation records this snapshot. The page link may show a newer release later.	−USD 46.74 million Calculation and evidence -42996000 − 3743000 USD Exact free cash flow: -46739000 USD 2018-01-01 – 2018-12-31: -42996000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 3743000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2018-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -46739000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42996000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459021008270/rcus-10k_20201231.htm#2503603 Filing: 000156459021008270 Input fundies:CapitalExpenditure: 3743000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000156459021008270/rcus-10k_20201231.htm#2531465 Filing: 000156459021008270 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 84.71 million Exact value Exact value: -84710000 USD 2019-01-01 – 2019-12-31: -84710000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2019-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -84710000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -84710000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017022001788/rcus-20211231.htm#3355305 Filing: 000095017022001788 The citation records this snapshot. The page link may show a newer release later.	−USD 73.46 million Exact value Exact value: -73462000 USD 2019-01-01 – 2019-12-31: -73462000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2019-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -73462000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -73462000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017022001788/rcus-20211231.htm#2181414 Filing: 000095017022001788 The citation records this snapshot. The page link may show a newer release later.	USD 1.93 million Exact value Exact value: 1925000 USD 2019-01-01 – 2019-12-31: 1925000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2019-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 1925000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1925000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017022001788/rcus-20211231.htm#2209723 Filing: 000095017022001788 The citation records this snapshot. The page link may show a newer release later.	−USD 75.39 million Calculation and evidence -73462000 − 1925000 USD Exact free cash flow: -75387000 USD 2019-01-01 – 2019-12-31: -73462000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1925000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2019-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -75387000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -73462000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017022001788/rcus-20211231.htm#2181414 Filing: 000095017022001788 Input fundies:CapitalExpenditure: 1925000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017022001788/rcus-20211231.htm#2209723 Filing: 000095017022001788 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 123 million Exact value Exact value: -123000000 USD 2020-01-01 – 2020-12-31: -123000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2020-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -123000000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -123000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005112/rcus-20221231.htm#2748082 Filing: 000095017023005112 The citation records this snapshot. The page link may show a newer release later.	USD 111 million Exact value Exact value: 111000000 USD 2020-01-01 – 2020-12-31: 111000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2020-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: 111000000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 111000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005112/rcus-20221231.htm#1959257 Filing: 000095017023005112 The citation records this snapshot. The page link may show a newer release later.	USD 3 million Exact value Exact value: 3000000 USD 2020-01-01 – 2020-12-31: 3000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2020-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 3000000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005112/rcus-20221231.htm#1994413 Filing: 000095017023005112 The citation records this snapshot. The page link may show a newer release later.	USD 108 million Calculation and evidence 111000000 − 3000000 USD Exact free cash flow: 108000000 USD 2020-01-01 – 2020-12-31: 111000000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2020-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: 108000000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 111000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005112/rcus-20221231.htm#1959257 Filing: 000095017023005112 Input fundies:CapitalExpenditure: 3000000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000095017023005112/rcus-20221231.htm#1994413 Filing: 000095017023005112 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 53 million Exact value Exact value: 53000000 USD 2021-01-01 – 2021-12-31: 53000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2021-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: 53000000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 53000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000052/rcus-20231231.htm#1383857 Filing: 000172452124000052 The citation records this snapshot. The page link may show a newer release later.	−USD 256 million Exact value Exact value: -256000000 USD 2021-01-01 – 2021-12-31: -256000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2021-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -256000000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -256000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000052/rcus-20231231.htm#1077311 Filing: 000172452124000052 The citation records this snapshot. The page link may show a newer release later.	USD 26 million Exact value Exact value: 26000000 USD 2021-01-01 – 2021-12-31: 26000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2021-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 26000000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000052/rcus-20231231.htm#1086127 Filing: 000172452124000052 The citation records this snapshot. The page link may show a newer release later.	−USD 282 million Calculation and evidence -256000000 − 26000000 USD Exact free cash flow: -282000000 USD 2021-01-01 – 2021-12-31: -256000000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 26000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2021-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -282000000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -256000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000052/rcus-20231231.htm#1077311 Filing: 000172452124000052 Input fundies:CapitalExpenditure: 26000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000052/rcus-20231231.htm#1086127 Filing: 000172452124000052 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 267 million Exact value Exact value: -267000000 USD 2022-01-01 – 2022-12-31: -267000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2022-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -267000000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -267000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000040/rcus-20241231.htm#1484062 Filing: 000172452125000040 The citation records this snapshot. The page link may show a newer release later.	USD 438 million Exact value Exact value: 438000000 USD 2022-01-01 – 2022-12-31: 438000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2022-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: 438000000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 438000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000040/rcus-20241231.htm#1166017 Filing: 000172452125000040 The citation records this snapshot. The page link may show a newer release later.	USD 6 million Exact value Exact value: 6000000 USD 2022-01-01 – 2022-12-31: 6000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2022-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 6000000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000040/rcus-20241231.htm#1174860 Filing: 000172452125000040 The citation records this snapshot. The page link may show a newer release later.	USD 432 million Calculation and evidence 438000000 − 6000000 USD Exact free cash flow: 432000000 USD 2022-01-01 – 2022-12-31: 438000000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 6000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2022-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: 432000000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 438000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000040/rcus-20241231.htm#1166017 Filing: 000172452125000040 Input fundies:CapitalExpenditure: 6000000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000040/rcus-20241231.htm#1174860 Filing: 000172452125000040 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 307 million Exact value Exact value: -307000000 USD 2023-01-01 – 2023-12-31: -307000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2023-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -307000000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -307000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1496899 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	−USD 306 million Exact value Exact value: -306000000 USD 2023-01-01 – 2023-12-31: -306000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2023-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -306000000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -306000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1147960 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	USD 24 million Exact value Exact value: 24000000 USD 2023-01-01 – 2023-12-31: 24000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2023-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 24000000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1156751 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	−USD 330 million Calculation and evidence -306000000 − 24000000 USD Exact free cash flow: -330000000 USD 2023-01-01 – 2023-12-31: -306000000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 24000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2023-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -330000000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -306000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1147960 Filing: 000172452126000009 Input fundies:CapitalExpenditure: 24000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1156751 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 283 million Exact value Exact value: -283000000 USD 2024-01-01 – 2024-12-31: -283000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2024-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -283000000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -283000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1496157 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	−USD 170 million Exact value Exact value: -170000000 USD 2024-01-01 – 2024-12-31: -170000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2024-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -170000000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -170000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1147334 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	USD 6 million Exact value Exact value: 6000000 USD 2024-01-01 – 2024-12-31: 6000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2024-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 6000000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1156194 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	−USD 176 million Calculation and evidence -170000000 − 6000000 USD Exact free cash flow: -176000000 USD 2024-01-01 – 2024-12-31: -170000000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 6000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2024-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -176000000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -170000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1147334 Filing: 000172452126000009 Input fundies:CapitalExpenditure: 6000000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1156194 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 353 million Exact value Exact value: -353000000 USD 2025-01-01 – 2025-12-31: -353000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Net Income: -353000000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -353000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1495416 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	−USD 482 million Exact value Exact value: -482000000 USD 2025-01-01 – 2025-12-31: -482000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Operating Cash Flow: -482000000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -482000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1146709 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	USD 2 million Exact value Exact value: 2000000 USD 2025-01-01 – 2025-12-31: 2000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Capital Expenditure: 2000000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1155638 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.	−USD 484 million Calculation and evidence -482000000 − 2000000 USD Exact free cash flow: -484000000 USD 2025-01-01 – 2025-12-31: -482000000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 2000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Arcus Biosciences, Inc. · 2025-12-31 Arcus Biosciences, Inc. (edgar:1724521) Free cash flow: -484000000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1724521?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -482000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1146709 Filing: 000172452126000009 Input fundies:CapitalExpenditure: 2000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/rcus-20251231.htm#1155638 Filing: 000172452126000009 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

50 filings · 2,393 latest values · 2,393 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001724521, 1724521, RCUS, edgar:1724521

Also known as Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation